20 Nov 2026 · Happened
Saxenda Discontinued in the US: Last Shipments in Late January 2027 (Nov 2026)
Novo is discontinuing Saxenda in the US, with last shipments to wholesalers in late January 2027. Why, what it means for you, and today's prices for the alternatives.
4 Nov 2026 · Status: pending
CagriSema FDA Decision: Expected in Q4 2026, Not Yet Approved (Nov 2026)
CagriSema is not FDA-approved yet. Novo filed in December 2025 and expects the US decision in Q4 2026. Trial results, launch timing and what you can buy today.
28 Oct 2026 · Status: pending
Retatrutide Phase 3: 28.3% Average Weight Loss at 80 Weeks, FDA Filing Planned for Q1 2027 (Nov 2026)
Lilly's retatrutide cut weight 28.3% at 80 weeks in TRIUMPH-1 and beat Ozempic head to head. Not approved yet: Lilly plans to file in Q1 2027. What it means for cost.
1 Jul 2026 · Happened
Medicare GLP-1 Bridge: $50 a Month for Wegovy, Zepbound KwikPen and Foundayo (Nov 2026)
Since July 1, 2026, Medicare's GLP-1 Bridge charges a $50 copay for Wegovy, Foundayo and the Zepbound KwikPen. Who qualifies, how long it runs and what cash costs.







